Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Multimodal discovery of distinct tumor ecosystems for classic Hodgkin lymphoma

Shengqin Su, Ajay Subramanian, Timothy Flerlage et al. Nov 03, 2025 pp. 1783-1783 10.1182/blood-2025-1783

Abstract Introduction: Classic Hodgkin lymphoma (cHL) is distinguished by a unique tumor microenvironment (TME), which is comprised of rare...

A proteomic signature derived by ensemble machine learning for predicting relapse in pediatric B cell acute lymphoblastic leukemia

Veronica Yeung, Edward Ni, Spencer Boisjoli et al. Nov 03, 2025 pp. 5144-5144 10.1182/blood-2025-5144

Abstract Introduction: Relapsed pediatric acute lymphoblastic leukemia (ALL) requires intensive treatment, increasing the risk of late effec...

IL-6 and ferritin levels predict the severity of cytopenia post CAR T-cell treatment with axi-cel for B cell lymphoma

Alfadil Haroon, Syed Ahmed, Reem Ahmad Awad et al. Nov 03, 2025 pp. 5495-5495 10.1182/blood-2025-5495

Abstract Background: Chimeric Antigen Receptor (CAR) T-cell therapy is a promising treatment for hematologic malignancies such as B cell lym...

Study of video electroencephalogram features for predicting 28-day survival in critical hematologic patients with disorders of consciousness

Peiran Yu, Wanying Li, Jiajing Wang et al. Nov 03, 2025 pp. 7863-7863 10.1182/blood-2025-7863

Abstract Background: Critical hematologic patients frequently develop disorders of consciousness due to infection, metabolic derangements, o...

A zebrafish model of parn deficiency identifies altered lipid metabolism as a novel therapeutic target for restoring hematopoiesis in dyskeratosis congenita

Sarada Ketharnathan, Serkan Dogan, Sujata Pokharel et al. Nov 03, 2025 pp. 1438-1438 10.1182/blood-2025-1438

Abstract Dyskeratosis congenita is a type of inherited bone marrow failure syndrome (IBMFS) that is characterized by multilineage cytopenia...

Sox11-induced reprogramming of B2 cells to a B1a-like phenotype promotes Mantle Cell Lymphoma in mice

Tim Pieters, Luca Pagliaro, André De Almeida et al. Nov 03, 2025 pp. 143-143 10.1182/blood-2025-143

Abstract Background: Mantle cell lymphoma (MCL) is a highly aggressive B cell lymphoma that accounts for 6% of all non-Hodgkin lymphomas and...

Repurposing of disulfiram as a novel therapeutic agent to treat crebbp-mutant diffuse large B-cell lymphoma (DLBCL)

James Boncan, Lili Dimitrova, Priyankush Choudhury et al. Nov 03, 2025 pp. 1524-1524 10.1182/blood-2025-1524

Abstract Diffuse large B cell lymphoma (DLBCL) is an aggressive genetically heterogenous haematological malignancy and the most common histo...

Outcomes of patients with relapsed/refractory FLT3mut+ Acute Myeloid Leukemia who resumed gilteritinib therapy after HSCT: Post hoc analysis from the ADMIRAL and COMMODORE trials

Mark Levis, Alexander Perl, Jianda Hu et al. Nov 03, 2025 pp. 42-42 10.1182/blood-2025-42

Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative option for patients with relapsed/refractory (R...

Impact of addition of anti-CD38 monoclonal antibody to first line therapy in newly diagnosed multiple myeloma with high risk cytogenetics: A systematic review and meta-analysis of randomized trials

Greeshma Gaddipati, Sandeep Guntuku, Prerna Mewawalla et al. Nov 03, 2025 pp. 7589-7589 10.1182/blood-2025-7589

Abstract Introduction: Quadruplet regimen with anti-CD38 monoclonal antibodies (mAb) with a proteasome inhibitor (PI) and immunomodulatory d...

CD66c expression is an important factor in adult B-cell acute lymphoblastic leukemia

Mai Kawazoe, Yasuhiro Nakashima, Soichiro Nakako et al. Nov 03, 2025 pp. 6889-6889 10.1182/blood-2025-6889

Abstract In B-cell acute lymphoblastic leukemia (B-ALL), a measurable residual disease (MRD) level of <0.01% after remission inductio...

Poor survival and temporal trends in blastic plasmacytoid dendritic cell neoplasm: A SEER 2000–2022 analysis

Priyanka Nagdev, nishita shetty, Mythri Chittilla Nov 03, 2025 pp. 6380-6380 10.1182/blood-2025-6380

Abstract Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignanc...

A TLR4-HSP70 efferocytic program in thymic macrophages sustains thymic homeostasis and T cell output

Andri Leo Lemarquis, Daniel Ghazarian, Miriam Martinez et al. Nov 03, 2025 pp. 160-160 10.1182/blood-2025-160

Abstract T cell reconstitution is essential for immune recovery after hematopoietic cell transplantation (HCT) and requires a functional thy...

T cell receptor costimulation blockade effectively prevents acute graft versus host disease without reducing the size or diversity of the T cell immune repertoire

Chiara Wychera, Alexandre Albanese, Steven Siegel et al. Nov 03, 2025 pp. 819-819 10.1182/blood-2025-819

Abstract Background: Both graft versus host disease (GVHD) and infections remain major causes of morbidity and non-relapse mortality after h...

Manual review of select hotspots may unmask clonal hematopoiesis variants at low levels in at-risk pediatric patients undergoing initial bone marrow sequencing

Fouad El-Dana, Tarek Elghetany, Michele Redell et al. Nov 03, 2025 pp. 6709-6709 10.1182/blood-2025-6709

Abstract Background: In hematopoietic stem cells, the acquisition of recurrent somatic mutations in select genes is linked to the developmen...

Humanistic and economic burden among caregivers of adults and children with sickle cell disease and recurrent vaso-occlusive crises

Lauren Lilly, Duncan Brown, Nanxin Li et al. Nov 03, 2025 pp. 1092-1092 10.1182/blood-2025-1092

Abstract Introduction: Sickle cell disease (SCD) is a chronic, inherited blood disorder characterized by recurrent pain episodes, frequent h...

Clinical efficacy and diagnostic value of metagenomic next-generation sequencing for pathogen detection in severe aplastic anemia patients with suspected infectious diseases

Jinsong JIA, Xiaojing Zhang, Bo Shao et al. Nov 03, 2025 pp. 2894-2894 10.1182/blood-2025-2894

Abstract Introduction: Aplastic anemia (AA) is a rare and life-threatening hematologic disorder, with infections posing significant mortalit...

Preclinical activity of investigational menin inhibitor DSP-5336 (Enzomenib)-based combinations against MLL1-rearranged (MLL-r) or mutant-NPM1 AML models

Warren Fiskus, Christopher Mill, Christine Birdwell et al. Nov 03, 2025 pp. 1497-1497 10.1182/blood-2025-1497

Abstract MLL1 (KMT2A, or MLL1) is a transcriptional regulator and a histone-lysine-N-methyltransferase. The N-terminus of MLL1 binds to the...

Venetoclax combined with five days of azacitidine for the treatment of previously untreated Acute Myeloid Leukemia (AML): Initial results of the prospective venaza-5S trial

Klaus Metzeler, Jens Przybilla, Anne Weigert et al. Nov 03, 2025 pp. 46-46 10.1182/blood-2025-46

Abstract Background: The combination of Azacitidine (AZA) and Venetoclax (VEN) has become the standard of care frontline treatment for AML p...

Splenectomy as a treatment for relapsed or refractory immune thrombotic thrombocytopenic purpura: A systematic review

Zahrah Talawala, Eric Han, Zahra Tauseef et al. Nov 03, 2025 pp. 1328-1328 10.1182/blood-2025-1328

Abstract Background: Immune Thrombotic Thrombocytopenic Purpura (iTTP) is a rare, life-threatening thrombotic microangiopathy caused by acqu...

Real-world comparative outcomes of CAR-T cell therapy versus pomalidomide-based regimens in relapsed/refractory multiple myeloma: A propensity-matched cohort study

Fayaz Khan, Madhu Bhargavi Chandra, Zuhair Alam Nov 03, 2025 pp. 5849-5849 10.1182/blood-2025-5849

Abstract Background Chimeric antigen receptor T-cell (CAR-T) therapies have become a key treatment option for patients with relapsed/refract...

Next generation sting agonist in combination with DNA methyltransferase inhibitors induce an apoptotic cell death mechanism driven by apoptosis in TP53-mutated Acute Myeloid Leukemia

Lora Stojanovic, Kaushlendra Tripathi, Monali Banerjee et al. Nov 03, 2025 pp. 3233-3233 10.1182/blood-2025-3233

Abstract Background TP53 mutations in acute myeloid leukemia (AML) are associated with resistance to...

Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomab

Benjamin Frost, Yannis Valtis, Yael Flamand et al. Nov 03, 2025 pp. 3329-3329 10.1182/blood-2025-3329

Abstract Introduction: Outcomes for adult patients (pts) with Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (B-...

Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma

Yasmin Karimi, Chan Cheah, Julie Vose et al. Nov 03, 2025 pp. 5513-5513 10.1182/blood-2025-5513

Abstract Introduction: Relapsed or refractory (R/R) large B-cell lymphoma (LBCL) is challenging to treat; there remains a need for more effe...

A pilot study evaluating the feasibility and usability of an mHealth application: SCD warrior

Nancy Asomaning, Matthew Xu, Ingrid Frey et al. Nov 03, 2025 pp. 4366-4366 10.1182/blood-2025-4366

Abstract BACKGROUND Sickle cell disease (SCD) is an inherited blood disorder that affects over 7 million individuals wor...

Trial in progress: A phase 3, randomized, double-blind, placebo-controlled study of axatilimab and corticosteroids as initial treatment for moderate to severe chronic graft-versus-host disease

Zachariah Defilipp, Maureen Bleam, Chuan Tian et al. Nov 03, 2025 pp. 4256-4256 10.1182/blood-2025-4256

Abstract Introduction: Chronic graft-versus-host disease (cGVHD) is an immune-mediated complication of allogeneic hematopoietic stem cell tr...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page